

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Anson Funds Management LP</u> (Last) (First) (Middle) 16000 DALLAS PARKWAY SUITE 800 (Street) DALLAS TX 75248 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>MEI Pharma, Inc. [MEIP]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 09/20/2023	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	
Rule 10b5-1(c) Transaction Indication <input type="checkbox"/> Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	09/20/2023		P		120,000	A	\$6.0093	782,528 ⁽¹⁾⁽²⁾	I	See footnotes ⁽³⁾
Common Stock	09/21/2023		P		33,600	A	\$6.4616	816,128 ⁽¹⁾⁽²⁾	I	See footnotes ⁽³⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		(A)	(D)					

1. Name and Address of Reporting Person*
Anson Funds Management LP
 (Last) (First) (Middle)
 16000 DALLAS PARKWAY
 SUITE 800
 (Street)
 DALLAS TX 75248
 (City) (State) (Zip)

1. Name and Address of Reporting Person*
Anson Advisors Inc.
 (Last) (First) (Middle)
 155 UNIVERSITY AVENUE
 SUITE 207
 (Street)
 TORONTO A6 M5H 3B7
 (City) (State) (Zip)

1. Name and Address of Reporting Person*
Nathoo Amin

(Last)	(First)	(Middle)
155 UNIVERSITY AVENUE		
SUITE 207		
(Street)		
TORONTO	Z4	M5H 3B7
(City)		
(State)	(Zip)	

1. Name and Address of Reporting Person*

[Kassam Moez](#)

(Last)	(First)	(Middle)
111 PETER STREET		
SUITE 904		
(Street)		
TORONTO	A6	M5V2H1
(City)		
(State)	(Zip)	

1. Name and Address of Reporting Person*

[Anson Management GP LLC](#)

(Last)	(First)	(Middle)
16000 DALLAS PARKWAY		
SUITE 800		
(Street)		
DALLAS	TX	75248
(City)		
(State)	(Zip)	

1. Name and Address of Reporting Person*

[Winson Bruce Ross](#)

(Last)	(First)	(Middle)
16000 DALLAS PARKWAY		
SUITE 800		
(Street)		
DALLAS	TX	75248
(City)		
(State)	(Zip)	

Explanation of Responses:

- The filing of this Form 4 shall not be construed as an admission that Anson Funds Management LP ("Anson"), Anson Management GP LLC, the general partner of Anson ("Anson GP"), Bruce R. Winson, the manager of Anson GP, Anson Advisors Inc. ("Anson Advisors"), Amin Nathoo, a director of Anson Advisors, or Moez Kassam, a director of Anson Advisors, is or was for the purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or otherwise the beneficial owner of any of the shares of Common Stock, \$0.00000002 par value (the "Common Stock"), of MEI Pharma, Inc. (the "Issuer") purchased by Anson Investments Master Fund LP, Anson East Master Fund LP and Anson Opportunities Master Fund LP (collectively, the "Funds"), each advised by Anson and Anson Advisors.
- Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.
- Anson and Anson Advisors hold indirectly 816,128 shares of Common Stock of the Issuer through the Funds, for which Anson and Anson Advisors are the Investment Advisors. Anson GP and Bruce R. Winson report the Common Stock held indirectly by the Funds because, as the general partner of Anson and the manager of Anson GP, respectively, at the time of purchase, they controlled the disposition and voting of the securities. Mr. Nathoo and Mr. Kassam report the Common Stock held indirectly by the Funds because, as the directors of Anson Advisors, at the time of purchase, they controlled the disposition and voting of the securities.

/s/ Bruce R. Winson, manager of Anson Management GP LLC, general partner of Anson Funds Management LP	09/22/2023
/s/ Bruce R. Winson, manager of Anson Management GP LLC	09/22/2023
/s/ Bruce R. Winson	09/22/2023
/s/ Amin Nathoo, director of Anson Advisors Inc.	09/22/2023
/s/ Amin Nathoo	09/22/2023
/s/ Moez Kassam	09/22/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
 ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
 Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

